09 May Thank You EpiVax!
RFTC Japan has received a donation of 775,978 Yen from Epivax
Dr. Agatsuma was the Head of Research and a member of the Executive Committee at Daiichi Sankyo. He was the innovator that led a team of researchers to develop Antibody Drug Conjugate (ADC) technology, including ADC against HER2, a critical cancer target for Breast Cancer. In other words, his ability to identify effective ways to attack cancer has contributed to better survival rates for breast cancer (and other cancers), not only in Japan, but everywhere in the world.
This donation is a significant way to remember his positive influence on science and his colleagues.
